日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Predictive power of tertiary lymphoid structure for prognosis and neoadjuvant chemotherapy response in HER2-positive breast cancer.

三级淋巴结构对 HER2 阳性乳腺癌预后和新辅助化疗反应的预测能力

Li Mengxi, Cao Jing, Wang Yueheng, Zhao Ziru, Ai Liqiang, Zhang Kejing

Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade

CXCL1和LY9的上调促进卵巢癌的BRCA样表达,并介导对PARP抑制剂和免疫检查点阻断的反应。

Chen, Tingting; Yu, Tong; Zhuang, Shuping; Geng, Yiding; Xue, Junwen; Wang, Jiayi; Ai, Liqiang; Chen, Bo; Zhao, Zhangxiang; Li, Yawei; Wang, Jinghao; Liang, Haihai; Xu, Yan; Gu, Yunyan

FDRdb: a manually curated database of fibrotic disease-associated RNAome and high-throughput datasets

FDRdb:一个人工整理的纤维化疾病相关RNA组和高通量数据集数据库

Wang, Chengyu; Chen, Tingting; Mu, Yuchen; Liang, Xuan; Xiong, Kai; Ai, Liqiang; Gu, Yunyan; Fan, Xingxing; Liang, Haihai

A transcriptional signature detects homologous recombination deficiency in pancreatic cancer at the individual level

转录特征可在个体水平上检测胰腺癌中的同源重组缺陷。

Zhuang, Shuping; Chen, Tingting; Li, Yawei; Wang, Yuquan; Ai, Liqiang; Geng, Yiding; Zou, Min; Liu, Kaidong; Xu, Huanhuan; Wang, Linzhu; Zhao, Zhangxiang; Chang, Zhiqiang; Gu, Yunyan

Revealing biomarkers associated with PARP inhibitors based on genetic interactions in cancer genome

基于癌症基因组中的基因相互作用,揭示与PARP抑制剂相关的生物标志物

Dong, Qi; Liu, Mingyue; Chen, Bo; Zhao, Zhangxiang; Chen, Tingting; Wang, Chengyu; Zhuang, Shuping; Li, Yawei; Wang, Yuquan; Ai, Liqiang; Liu, Yaoyao; Liang, Haihai; Qi, Lishuang; Gu, Yunyan